Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4-Reference-Cited by-同舟云学术

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

Published:2022-08-05 Issue:13 Volume:23 Page:1503-1510
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Meuth Sven G¹^ORCID,Bayas Antonios²^ORCID,Kallmann Boris³,Linker Ralf⁴^ORCID,Rieckmann Peter⁵^ORCID,Wattjes Mike P⁶^ORCID,Mäurer Mathias⁷,Kleinschnitz Christoph⁸^ORCID

Affiliation:

1. Klinik für Neurologie des Universitätsklinikums Düsseldorf, Düsseldorf, Germany

2. Klinik für Neurologie und Klinische Neurophysiologie, Medizinische Fakultät, Universität Augsburg, Augsburg, Germany

3. Multiple Sklerose Zentrum Bamberg, Bamberg, Germany

4. Klinik und Poliklinik für Neurologie, Universitätsklinikum Regensburg, Regensburg, Germany

5. Abteilung für Neurologie, Medical Park Loipl, Regensburg, Germany

6. Department of diagnostic and interventional Neuroradiology, Hannover Medical School, Hannover, Germany

7. Klinik für Neurologie, Juliusspital Würzburg Klinikum Würzburg Mitte gGmbH, Würzburg, Germany

8. Klinik für Neurologie, Universitätsklinikum Essen, Essen, Germany

Funder

Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2106783

Reference47 articles.

1. EMA summary of product charateristics: mavenclad® (cladribine tablets) [cited 2022 Mar 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf.

2. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

3. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

4. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

5. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review;Multiple Sclerosis and Related Disorders;2024-10

2. Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice;Neurology and Therapy;2024-08-03

3. Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 – Results from a German cladribine cohort;Multiple Sclerosis and Related Disorders;2024-08

4. Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model;Multiple Sclerosis Journal;2024-06-10

5. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis;CNS Drugs;2024-03-15